迈得医疗公告，2025年上半年营业收入1.41亿元，同比下降14.75%。净利润604.51万元，同比下降 38.81%。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688310 | 迈得医疗 | 19.23 | -6.24% | 14.47万 | 2.89亿 | | 301312 | 智立方 | 52.80 | -5.78% | 11.83万 | 6.45亿 | | 301568 | 思泰克 | 50.22 | -5.69% | 6.91万 | 3.59亿 | | 300461 | 田中精机 | 21.52 | -5.57% | 7.53万 | 1.67亿 | | 300278 | 华昌达 | 5.97 | -5.54% | 80.36万 | 4.95 Z | | 688329 | 艾隆科技 | 21.59 | -4.85% | 2.50万 | 5528.14万 | | 605288 | 凯迪股份 | 69.37 | -4.63% | 2.38万 | 1.69 Z | | 301512 | 智信精密 | 45.49 | -4.43% | 1.57万 | 7387.17万 | | 300802 | 矩子科技 | ...

8月27日，迈得医疗跌5.07%，截至发稿，报19.47元/股，成交2.68亿元，换手率8.07%，总市值32.36亿 元。 融通健康产业灵活配置混合A/B（000727）基金经理为万民远。 资料显示，迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城，成立日期2003年3月 10日，上市日期2019年12月3日，公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为：安全输注类连线机42.18%，血液净化类连线机37.90%，安全输注类单机14.04%， 其他类5.87%。 从迈得医疗十大流通股东角度 数据显示，融通基金旗下1只基金位居迈得医疗十大流通股东。融通健康产业灵活配置混合A/B （000727）一季度减持156股，持有股数259.98万股，占流通股的比例为1.56%。根据测算，今日浮亏损 失约270.38万元。 融通健康产业灵活配置混合A/B（000727）成立日期2014年12月25日，最新规模20.74亿。今年以来收益 23.63%，同类排名3072/8194；近一年收益47%，同类排名2642/7963；成立以来收益198.7%。 责任编辑：小浪快报 截至发 ...

证券时报·数据宝统计，截至今日下午13:59，上证综指3884.87点，收于五日均线之上，涨跌幅0.03%， A股总成交额为21403.55亿元。到目前为止，今日有832只A股价格突破了五日均线，其中乖离率较大的 个股有嘉亨家化、久祺股份、迈得医疗等，乖离率分别为14.97%、14.66%、12.65%；博盈特焊、一彬 科技、永安行等个股乖离率较小，刚刚站上五日均线。 8月26日突破五日均线个股乖离率排名 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 300955 | 嘉亨家 化 | 20.02 | 22.59 | 21.33 | 24.52 | 14.97 | | 300994 | 久祺股 份 | 19.99 | 13.72 | 18.95 | 21.73 | 14.66 | | 688310 | 迈得医 疗 | 18.99 | 12.32 | 18.75 | 21.12 | 12.65 ...

8月26日盘中科创板股迈得医疗涨停，截至10:53，股价报21.30元，成交2.05亿元，换手率6.38%，振幅 21.30%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 科创板个股中，截至发稿上涨的共有262只，涨幅在10%以上的共有10只，涨幅较高的有迈得医疗、开 普云、电气风电等，分别上涨20.00%、20.00%、13.98%，下跌的有315只，跌幅较大的有井松智能、盛 科通信-U、芯原股份，分别下跌9.41%、9.20%、9.02%。 （文章来源：证券时报网） 资金面上，迈得医疗上一交易日主力资金净流出2782.52万元，近5日净流出4042.84万元。 融资融券数据显示，该股最新（8月25日）两融余额为7309.13万元，其中，融资余额为7309.13万元，较 上一个交易日减少27.19万元，降幅为0.37%；近10日两融余额合计增加1006.35万元，增幅为15.97%， 其间融资余额增长15.97%。（数据宝） ...

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，20日-22日，迈得医疗分别获融资买入0.03亿元、0.08亿元、0.16亿元。 8月22日，沪深两融数据显示，迈得医疗获融资买入额0.16亿元，居两市第1250位，当日融资偿还额0.11 亿元，净买入438.98万元。 ...

Core Viewpoint - The company is making progress in its contact lens business and aims to achieve commercialization within the year [1][4]. Group 1: Company Overview - As of August 15, 2025, the company's stock price closed at 18.33 yuan, up 4.09% from the previous week [1]. - The company has a total market capitalization of 3.047 billion yuan, ranking 69th out of 78 in the automation equipment sector and 4456th out of 5152 in the A-share market [1]. Group 2: Contact Lens Business Development - The domestic contact lens market is dominated by four major international players: Johnson & Johnson, CooperVision, Alcon, and Bausch & Lomb, with the industry still in its early stages in mainland China [1]. - The company is currently in the customer engagement and business development phase for its contact lens business, with online platforms being established to achieve commercialization this year [2]. - The company plans to integrate CDMO (Contract Development and Manufacturing Organization) with its own brand sales, starting with hydrogel products and later expanding to silicone hydrogel and functional soft lenses [2]. Group 3: Production Capacity and Quality - The company is applying for registration certificates for daily disposable soft contact lenses and currently operates four production lines, each with an annual capacity of 18 million pieces [2][4]. - The production yield of the contact lens lines is currently fluctuating as the company focuses on sample production and diversifying its product range [2]. Group 4: Future Plans and Financial Performance - The company will continue to focus on material research, product certification, brand launch, new product development, and cost optimization in its contact lens business [3]. - The company’s main business is under pressure due to reduced investment willingness from downstream clients and increased domestic competition, but blood purification equipment continues to grow due to domestic substitution [3]. - As of the end of 2024, the company has 21 orders for its drug-device combination products, which are expected to be a new growth point for 2025 [3][4]. - The company's contract liabilities reached 157.8464 million yuan, a 59.70% increase from the previous year, marking a three-year high, primarily driven by orders for drug-device combination and blood purification equipment [3][4].

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 最近三个交易日，7日-11日，迈得医疗分别获融资买入0.20亿元、0.05亿元、0.11亿元。 8月11日，沪深两融数据显示，迈得医疗获融资买入额0.11亿元，居两市第1292位，当日融资偿还额0.22 亿元，净卖出1113.19万元。 ...

Core Insights - Recent announcements from numerous listed companies indicate that significant shareholders are planning substantial share buybacks, reflecting a positive sentiment towards the companies' future development and long-term investment value [1][2][4]. Group 1: Shareholder Buyback Plans - Huaxi Biological announced a plan for its controlling shareholder to buy back shares worth between 200 million and 300 million yuan within six months, utilizing self-owned or self-raised funds [2]. - Daodaoquan's controlling shareholder plans to increase its stake by 50 million to 100 million yuan, with funding sourced from self-owned funds and a special loan of up to 90 million yuan from a bank [2][4]. - Ailuo Energy's controlling shareholder has already bought back shares worth approximately 999.87 thousand yuan and intends to continue the buyback plan, with a total planned investment between 20 million and 30 million yuan [5]. Group 2: Market Reactions and Implications - The increase in share buybacks has led to some shareholders reaching the regulatory threshold for significant shareholding, which has drawn market attention [5][6]. - As of August 11, 699 listed companies or significant shareholders have received buyback loans totaling approximately 1,425.23 billion yuan, indicating a strong trend in leveraging loans for share repurchases [7]. - Shandong Gold's controlling shareholder has secured a loan commitment of up to 900 million yuan from a bank for share buybacks, with plans to invest between 500 million and 1 billion yuan over the next year [7].

Market Overview - The Shanghai Composite Index closed at 3602.13 points, with a gain of 0.53% [1] - The total trading volume of A-shares reached 10185.93 billion yuan [1] Technical Analysis - A total of 29 A-shares experienced a death cross between the 5-day and 10-day moving averages today [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xiongdi Technology: 5-day MA down by 1.70% from the 10-day MA [1] - Sanwei Xinan: 5-day MA down by 1.11% from the 10-day MA [1] - Jinling Sports: 5-day MA down by 1.10% from the 10-day MA [1] Individual Stock Performance - Xiongdi Technology (300546): Today's change -0.23%, latest price 26.47 yuan, 5-day MA 27.31 yuan, 10-day MA 27.78 yuan [1] - Sanwei Xinan (688489): Today's change -0.80%, latest price 39.85 yuan, 5-day MA 40.62 yuan, 10-day MA 41.08 yuan [1] - Jinling Sports (300651): Today's change +0.89%, latest price 21.48 yuan, 5-day MA 23.82 yuan, 10-day MA 24.09 yuan [1] - Other notable stocks include: - Huanrui Century (000892): Today's change -0.86%, latest price 4.59 yuan [1] - Junshi Biological (688180): Today's change +0.45%, latest price 37.83 yuan [1] - Yihau New Materials (301176): Today's change -1.64%, latest price 30.65 yuan [1] Additional Stock Data - Other stocks with notable performance include: - Guanghe Technology (001389): Today's change -2.81%, latest price 62.20 yuan [1] - Kehua Data (002335): Today's change -2.13%, latest price 41.44 yuan [1] - ST Ruihe (002620): Today's change +0.26%, latest price 3.84 yuan [1] - The performance of these stocks indicates a mixed sentiment in the market, with some stocks showing declines while others remain stable or increase slightly [1][2]